Asterisk Inc. (TYO:6522)

Verve Therapeutics Cash Flow Statement

Financials in millions JPY. Fiscal year is September - August.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	May 31, 2025	Aug 31, 2024	Aug 31, 2023	Aug 31, 2022	Aug 31, 2021	Aug 31, 2020
Net Income	-	-280	-177	474	266	-
Depreciation & Amortization	-	66	48	18	41	-
Loss (Gain) From Sale of Assets	-	-	-	-	-18	-
Loss (Gain) From Sale of Investments	-	103	-	-	-	-
Other Operating Activities	-	66	-158	-162	-2	-
Change in Accounts Receivable	-	-115	63	-159	179	-
Change in Inventory	-	71	-357	297	-223	-
Change in Accounts Payable	-	-46	-18	-83	13	-
Change in Other Net Operating Assets	-	61	-88	-85	124	-
Operating Cash Flow	-	-74	-687	300	380	-
Operating Cash Flow Growth	-	-	-	-21.05%	-	-
Capital Expenditures	-	-25	-352	-395	-302	-
Sale (Purchase) of Intangibles	-	-2	-23	-9	-1	-
Investment in Securities	-	-	-101	-104	-	-
Other Investing Activities	-	-	-27	2	-	-
Investing Cash Flow	-	-27	-491	-518	-303	-
Short-Term Debt Issued	-	205	460	-	91	-
Long-Term Debt Issued	-	100	-	-	90	-
Total Debt Issued	-	305	460	-	181	-
Short-Term Debt Repaid	-	-	-	-361	-	-
Long-Term Debt Repaid	-	-9	-	-137	-164	-
Total Debt Repaid	-	-9	-	-498	-164	-
Net Debt Issued (Repaid)	-	296	460	-498	17	-
Issuance of Common Stock	-	2	31	1,278	-	-
Other Financing Activities	-	-	-	-	-1	-
Financing Cash Flow	-	298	491	780	16	-
Foreign Exchange Rate Adjustments	-	18	3	25	7	-
Miscellaneous Cash Flow Adjustments	-	-	-	-	1	-
Net Cash Flow	-	215	-684	587	101	-
Free Cash Flow	-	-99	-1,039	-95	78	-
Free Cash Flow Margin	-	-6.27%	-59.07%	-3.95%	4.35%	-
Free Cash Flow Per Share	-	-13.92	-146.66	-13.27	15.23	-
Cash Interest Paid	-	2	1	-	3	-
Cash Income Tax Paid	-	-63	160	163	31	-
Levered Free Cash Flow	-	-10.5	-987.63	-169	79.75	-
Unlevered Free Cash Flow	-	-8.63	-987.63	-169	82.25	-
Change in Net Working Capital	-293.55	-93	540	33	-203	100

Source: S&P Global Market Intelligence. Standard template. Financial Sources.